The Spanish health secretary says Lilly’s Kisunla and Eisai/Biogen’s Leqembi are too expensive in relation to the benefits they offer, but could help prepare the health system for future innovations in Alzheimer’s.
The Spanish health secretary says Lilly’s Kisunla and Eisai/Biogen’s Leqembi are too expensive in relation to the benefits they offer, but could help prepare the health system for future innovations in Alzheimer’s.